Physician profile
Matthew Christopher Lee
NPI 1386705283
$76,962.25
in general payments reported to CMS, 2019-2025
15 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $10K · 2021: $15K · 2022: $288 · 2023: $6,855 · 2024: $223 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,630 · Consulting Fee: $1,600 · Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,630.48 |
| Consulting Fee | $1,600.00 |
| Food and Beverage | $1,083.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $54,410.03 | 2019-2020 | |
| Medtronic, INC. | $14,915.42 | 2021-2025 | Unid_pass, Atlantis Anterior Cervical Plate System, O-Arm |
| Cgg Medical INC | $4,628.32 | 2023-2025 | |
| Si-Bone, INC. | $1,936.61 | 2019-2025 | |
| Arthrex, INC. | $601.16 | 2023 | |
| Bioventus LLC | $144.80 | 2021-2023 | |
| Abbott Laboratories | $112.73 | 2025 | Eterna |
| Stryker Corporation | $76.87 | 2022 | |
| Glaxosmithkline, LLC. | $33.75 | 2020 | |
| Zyla Life Sciences, INC. | $24.11 | 2020 | |
| Globus Medical, INC. | $19.80 | 2025 | Vyrsa V1 |
| Orthofix Medical, INC. | $18.97 | 2024 | Stim On Track |
| Amgen INC. | $15.58 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $12.97 | 2022 | |
| Karyopharm Therapeutics INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.